TOTAL: $182.65M | ||||
Year to Date: $649.70M | ||||
Company (Symbol)#* |
Partner (Country) |
Amt. (M) |
Triggering Event |
Details (Date) |
|
| ||||
Acadia Pharmaceuticals Inc. (ACAD) |
Allergan Inc. (NYSE:AGN) |
ND |
Milestone payment |
Tied to the initiation of an exploratory glaucoma trial (7/16) |
| ||||
Amorfix Life Sciences Ltd. (Canada; CDNX:AMF) |
Biogen Idec Inc. (BIIB) |
$0.15 |
Investment milestone |
Biogen Idec will subscribe for 91,445 shares at C$1.76 ($1.69) per share for gross proceeds of $150,000; the investment allows Biogen Idec to retain its exclusive worldwide option to license Amorfix's drug candidates for amyotrophic lateral sclerosis (7/23) |
| ||||
Biota Holdings Ltd. (Australia; ASX:BTA) |
MedImmune Inc. (unit of AstraZeneca plc; UK; LSE:MDI) |
$3 |
Milestone payment |
For the start of a Phase Ia trial of BTA9881 for respiratory syncytial virus (7/17) |
| ||||
ChemoCentryx Inc.* |
GlaxoSmithKline plc (UK) |
$5 |
Milestone payment |
For progress in their small-molecule CCR1 discovery and development program; it was triggered by the acceptance of ChemoCentryx's orally bioavailable small molecule, CCX354, as a candidate for full development (7/24) |
| ||||
Durect Corp. (DRRX) |
Nycomed A/S (Denmark) |
$8 |
Milestone payment |
For Phase IIb data showing statistically significant reductions in pain with Posidur when treating patients undergoing inguinal hernia repair (7/17) |
| ||||
Galapagos NV (Belgium; LSE:GLPG) |
Boehringer Ingelheim GmbH (Germany) |
ND |
Milestone payment |
Galapagos said its BioFocus DPI service division received the payment in relation to its autoimmune discovery research collaboration with Boehringer Ingelheim (7/20) |
| ||||
ImmunoGen Inc. (IMGN) |
Genentech Inc. (NYSE:DNA) |
$5 |
Milestone payment |
For the initiation of a Phase II breast cancer trial with trastuzumab-DM1 (7/31) |
| ||||
InterMune Inc. (ITMN) |
F. Hoffmann-La Roche Ltd. (Switzerland) |
$10 |
Milestone payment |
InterMune earned the milestone when Roche submitted an amended clinical trial authorization in Europe for ITMN-191 in chronic hepatitis C patients (7/25) |
| ||||
Medarex Inc. (MEDX) |
Novartis Pharma AG (Switzerland) |
ND |
Milestone payment |
For advancing ACZ885 into a Phase III trial (7/18) |
| ||||
Neuroptix Corp.* |
Merck & Co. Inc. |
$1 |
Milestone payment |
Related to its Alzheimer's disease diagnostic collaboration (7/16) |
| ||||
NicOx SA (France; FSE:NXO) |
Merck & Co. Inc. |
$5 |
Milestone payment |
For the initiation of the first in a series of planned clinical trials for the lead candidate from an agreement to develop nitric oxide-donating antihypertensive agents using NicOx's technology (7/16) |
| ||||
Pharmacopeia Drug Discovery Inc. (PCOP) |
GlaxoSmithKline plc (UK) |
$0.5 |
Milestone payment |
For the identification of a lead compound for advancement six months ahead of the original schedule; the compound is being evaluated as a treatment for inflammatory pain, and will now enter lead optimization (7/17) |
| ||||
Santarus Inc. (SNTS) |
Schering-Plough Healthcare Products Inc. (division of Schering-Plough Corp.) |
$5 |
Milestone payment |
For clinical development progress on a license agreement for proton pump inhibitor products using Santarus' PPI technology (7/20) |
| ||||
Vivus Inc. (VVUS) |
KV Pharmaceutical Co. |
$140 |
Milestone payment |
Vivus won FDA approval of Evamist to treat severe vasomotor symptoms due to menopause, triggering the milestone payments (7/30) |
|
| ||||
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Private company. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
ASX = Australia Stock Exchange; CDNX = Canadian Venture Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange. | ||||
